GlycoNex Incorporation (TPEX:4168)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
New Antibody Drug Department	37.86M	14.70M	2.54M	30.09M	5.48M
New Antibody Drug Department Growth	157.54%	478.32%	-91.55%	449.50%	1113.97%
Total	37.86M	14.70M	2.54M	30.09M	5.48M
Total Growth	157.54%	478.32%	-91.55%	449.50%	1113.97%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Japan	37.82M	7.18M	1.61M	19.28M	3.12M
Japan Growth	426.51%	346.43%	-91.65%	517.20%	-
Taiwan	42.00K	7.52M	933.00K	468.00K	2.35M
Taiwan Growth	-99.44%	705.79%	99.36%	-80.10%	421.51%
India	-	-	-	10.34M	-
Total	37.86M	14.70M	2.54M	30.09M	5.48M
Total Growth	157.54%	478.32%	-91.55%	449.50%	1113.97%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 9, 2026

Data Sources Report a data error